Antitumor activity of PAbs generated by immunization with a novel HER3-targeting protein-based vaccine candidate in preclinical models

被引:1
作者
Bermudez-Abreut, Ernesto [1 ]
Baez, Gretchen Bergado [1 ]
Pestano, Melissa Martinez [1 ]
Attanasio, Giuseppe [2 ]
Castillo, Carlos Yordan Gonzales [1 ]
Fernandez, Diana Rosa Hernandez [1 ]
Alvarez-Arzola, Rydell [1 ]
Alimonti, Andrea [2 ,3 ,4 ,5 ]
Sanchez-Ramirez, Belinda [1 ]
机构
[1] Ctr Mol Immunol CIM, Immunol & Immunotherapy Div, Havana, Cuba
[2] Inst Oncol Res IOR, Dept Mol Oncol, Bellinzona, Switzerland
[3] Univ Svizzera Italiana, Fac Med, Lugano, Switzerland
[4] Univ Padua, Dept Med, Padua, Italy
[5] Oncol Inst Southern Switzerland, Med Oncol, Bellinzona, Switzerland
来源
FRONTIERS IN ONCOLOGY | 2024年 / 14卷
关键词
HER3; ErbB3; immunotherapy; cancer vaccines; PAbs; antitumor effect; CANCER; EGFR; HER3; INACTIVATION; EXPRESSION; APOPTOSIS; SURVIVAL; C-ERBB-3; RECEPTOR; GROWTH;
D O I
10.3389/fonc.2024.1472607
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Despite the cumulative evidence supporting HER3 as a target for antitumor therapies, no agents targeting HER3 have been approved for cancer treatment. Most of the agents evaluated in preclinical and clinical trials have been specific monoclonal antibodies (MAbs), with few examples of active immunotherapy directed against this receptor. However, some cancer vaccine formats may generate polyclonal antibodies (PAbs) that replicate the diverse effector mechanisms of MAbs, including ligand neutralization and receptor degradation. In this study, we developed a protein subunit-based monovalent vaccine candidate targeting the extracellular domain (ECD) of HER3. Immunization of mice with a formulation targeting murine ErbB3-ECD successfully overcome tolerance to this self-antigen, inducing high titers of ErbB3-specific PAbs. The antitumor potential of this formulation and the induced PAbs was demonstrated in vivo and in vitro in an ErbB3-overexpressing 3LL-D122-derived tumor model. The immunogenicity of the HER3-ECD-based vaccine candidate was confirmed by the induction of high titers of HER3-specific PAbs. Consistent with the initial results, HER3-ECD-targeting PAbs were cytotoxic in several human epithelial tumor cell lines and exerted antitumor effects in vivo. These results support the value of HER3 as a tumor antigen and the effector mechanisms of HER3-specific therapeutic MAbs, while suggesting the potential of the proposed vaccine candidate for the treatment of HER3-expressing carcinomas.
引用
收藏
页数:14
相关论文
共 47 条
[21]   Clinical development of HER3-targeting monoclonal antibodies: Perils and progress [J].
Jacob, Wolfgang ;
James, Ian ;
Hasmann, Max ;
Weisser, Martin .
CANCER TREATMENT REVIEWS, 2018, 68 :111-123
[22]  
Jacobsen HJ., 2015, Pan-HER, an antibody mixture simultaneously targeting EGFR, HER2, and HER3, effectively overcomes tumor heterogeneity and plasticity, V21, P4110, DOI [10.1158/1078-0432.CCR-14-3312, DOI 10.1158/1078-0432.CCR-14-3312]
[23]  
Jura N., 2009, Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3, V106, P21608, DOI [10.1073/pnas.0912101106, DOI 10.1073/PNAS.0912101106]
[24]  
Kawakami H., 2016, HER3 and its ligand, heregulin, as targets for cancer therapy, V11, P267, DOI [10.2174/1574892811666160418123221, DOI 10.2174/1574892811666160418123221]
[25]  
Kumar R., 2020, HER family in cancer progression: From discovery to 2020 and beyond, V147, P109, DOI [10.1016/bs.acr.2020.04.001, DOI 10.1016/BS.ACR.2020.04.001]
[26]   Role of erbB3 receptors in cancer therapeutic resistance [J].
Lee, Youngseok ;
Ma, Jian ;
Lyu, Hui ;
Huang, Jingcao ;
Kim, Aeree ;
Liu, Bolin .
ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2014, 46 (03) :190-198
[27]   A central role for HER3 in HER2-amplified breast cancer:: implications for targeted therapy [J].
Lee-Hoeflich, Si Tuen ;
Crocker, Lisa ;
Yao, Evelyn ;
Pham, Thinh ;
Munroe, Xander ;
Hoeflich, Klaus P. ;
Sliwkowski, Mark X. ;
Stern, Howard M. .
CANCER RESEARCH, 2008, 68 (14) :5878-5887
[28]   A potential autocrine loop between heregulin-alpha and erbB-3 receptor in human prostatic adenocarcinoma [J].
Leung, HY ;
Weston, J ;
Gullick, WJ ;
Williams, G .
BRITISH JOURNAL OF UROLOGY, 1997, 79 (02) :212-216
[29]   Very small size proteoliposomes derived from Neisseria meningitidis:: An effective adjuvant for generation of CTL responses to peptide and protein antigens [J].
Mesa, C ;
de León, J ;
Fernández, LE .
VACCINE, 2006, 24 (14) :2692-2699
[30]  
Miller MJ., 2014, HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells, V3, DOI [10.4161/21624011.2014.956012, DOI 10.4161/21624011.2014.956012]